The Ellipta® in asthma and chronic obstructive pulmonary disease: device characteristics and patient acceptability

Thomas L. Jones, Daniel M. Neville, Anoop J. Chauhan

    Research output: Contribution to journalArticlepeer-review

    913 Downloads (Pure)

    Abstract

    Asthma and chronic obstructive pulmonary disease are primarily treated with inhaled medication, but delivery of that medication to its site of action is problematic; patients’ ability to use inhalers will affect therapeutic response. Multiple inhaler devices are available but they are variably easy to use with consequent effects on compliance, intentional or otherwise. The Ellipta® device is a novel blister strip dry powder inhaler with medium resistance and a consistent delivered dose across a range of inspiratory flow rates. The Ellipta has proven easy to use and is preferred by patients across several evaluations and compared with other inhaler devices. The Ellipta is used to administer multiple inhaled medications, all in single daily-dose regimens, making it ideal for patients who struggle with complex inhaled therapy regimens.
    Original languageEnglish
    Pages (from-to)169-176
    JournalTherapeutic Delivery
    Volume9
    Issue number3
    Early online date9 Feb 2018
    DOIs
    Publication statusPublished - Feb 2018

    Fingerprint

    Dive into the research topics of 'The Ellipta® in asthma and chronic obstructive pulmonary disease: device characteristics and patient acceptability'. Together they form a unique fingerprint.

    Cite this